Exscientia plc

NasdaqGM:EXAI Voorraadrapport

Marktkapitalisatie: US$633.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Exscientia Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Exscientia is gedaald met een gemiddeld jaarlijks percentage van -41.2%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 33.8%. De inkomsten zijn groeide met een gemiddeld percentage van 9.2% per jaar.

Belangrijke informatie

-41.24%

Groei van de winst

-18.38%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.04%
Inkomstengroei9.18%
Rendement op eigen vermogen-58.93%
Nettomarge-881.79%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Seeking Alpha • Aug 08

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Summary Recursion Pharmaceuticals, Inc., the Salt Lake City based AI-driven drug developer, has agreed to combine businesses with Exscientia plc, a former rival, based in the UK. Neither company has delivered value for shareholders since their big-money IPOs, with share prices down by >75%. Both companies have proprietary drugs in their pipeline and programs in which they partner with Big Pharma companies to accelerate drug development. AI hype aside, this is a surprisingly underperforming sector of the stock market, with these types of companies struggling to develop strong pipelines or attract Pharma partners despite a high cash burn. As such, this deal's main strength is creating a larger company that can be more dominant within the industry. With that said, there are potentially valuable accretive data readouts later this year and early next for Recursion's rare disease candidates. Read the full article on Seeking Alpha
Analyseartikel • Jul 17

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 10

Exscientia: Too Much Pessimism

Summary Exscientia is using AI to improve drug discovery and address the low returns on investments in the pharmaceutical industry. While preclinical data generally looks promising, it is too early to know the overall impact of AI on drug discovery. While there is significant risk, Exscientia's low enterprise value and relatively integrated approach to AI-enabled drug discovery potentially provide an opportunity. Read the full article on Seeking Alpha
Seeking Alpha • May 22

Exscientia: Drug Discovery Platform Attracting Partners And Cash

Summary Exscientia plc's stock has underperformed the biotechnology and IT sectors, despite owning a tech platform attracting big pharma. The company uses AI to accelerate drug development and reduce time to market, potentially improving success rates. The partnerships with major pharmaceutical companies are generating cash inflows and the potential for future royalties. The company differentiates itself using its tech platform, which also uses LLMs (large language models) and Generative (Gen) AI. It is trading at about half its February 2023 peak as the AI hype has deflated but remains vulnerable to interest rate-related risks if the Federal Reserve adopts a hawkish tone. Read the full article on Seeking Alpha
Seeking Alpha • Feb 26

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Summary Exscientia's stock has been stagnant, with a 22% drop after the termination of its CEO due to inappropriate conduct. The company's pipeline efforts include CDK7 inhibitor GTAEXS617 and LSD1 inhibitor EXS74539, with clinical trials starting this year. Exscientia has entered into a collaboration with Sanofi, which could potentially bring in $45 million upfront and $300 million in milestones and royalties. Signals from the market, including shifts among institutional backers and a modest short interest, point to a guarded optimism, indicating potential hurdles in keeping up the momentum. In light of the amalgamation of breakthrough technology, solid financial health, yet mixed market sentiments, and recent executive upheaval, my recommendation shifts to "hold." Read the full article on Seeking Alpha
Analyseartikel • Jan 11

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Nov 12

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Exscientia plc ( NASDAQ:EXAI ) just released its latest third-quarter results and things are looking bullish. Revenue...
Analyseartikel • Aug 31

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Celebrations may be in order for Exscientia plc ( NASDAQ:EXAI ) shareholders, with the analysts delivering a...
Analyseartikel • Aug 25

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyseartikel • Jul 21

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia plc ( NASDAQ:EXAI ) shareholders will have a reason to smile today, with the analysts making substantial...
Analyseartikel • Apr 22

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Dec 30

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analyseartikel • Aug 31

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Today is shaping up negative for Exscientia plc ( NASDAQ:EXAI ) shareholders, with the analysts delivering a...
Seeking Alpha • Aug 15

Exscientia: Using AI To Power Drug Development

Today, we take our first look at Exscientia, a unique developmental concern using artificial intelligence or AI to help identify promising drug compounds. Its platform has drawn numerous collaboration deals from the likes of Sanofi and Bristol-Myers Squibb. An investment analysis follows in the paragraphs below. It's not treason if you win. ― Lisa Shearin, Bewitched & Betrayed Today, we put Exscientia (EXAI) in the spotlight for the first time. The developmental biotech concern has a fairly unique method of drug discovery and is headquartered across the pond. The shares came public less than a year ago but are not in 'Busted IPO' territory. What lies ahead for Exscientia? An analysis follows below. Seeking Alpha Company Overview Exscientia is located in Oxford in the United Kingdom. The company is focused on developing small molecule drug candidates. Exscientia's AI developmental platform enables it to design candidate drug molecules, as well as to provide patients with drug therapies. The firms provides end-to-end solution of AI and technologies for target identification, drug candidate design, translational models, and patient selection. The stock currently trades under $13.00 a share and sport a market capitalization just under $1.6 billion. June Company Presentation The company is bringing together a team of industry scientists and technologists which are looking to streamline the drug discovery process by extensively using AI to design and develop better molecules. June Company Overview The company has numerous collaboration partners including Bristol-Myers Squibb Company (BMY), the Bill & Melinda Gates Foundation, and Sanofi (SNY), which came on board this year. June Company Presentation In fact, the new partnership with Sanofi is the biggest news around Exscientia so far in 2022. This agreement provides for the development of up to 15 novel small molecule candidates across oncology and immunology in early January. June Company Presentation The deal provided a $100 million upfront payment to Exscientia which it recorded in April. The company can also earn up to $5.2 billion in additional milestone payments as well sales royalties in the high-single-digits to mid-teens. The agreement also provides an option for clinical co-investment by Exscientia to increase the royalty rate up to 21% on net sales of co-funded products. As can be seen below, this is one of many collaboration deals the company has in place. June Company Presentation Analyst Commentary & Balance Sheet Despite a market cap north of one and a half billion dollars, the company gets little intention from Wall Street. Most likely because of an overseas domicile. On June 13th, Morgan Stanley maintained its Equal Weight rating on the stock and lowered its price target a buck a share to $20. A month prior, Goldman Sachs had reissued its Buy rating and $20 price target on EXAI. That is the only analyst ratings I can find on the stock so far in 2022. June Company Overview Just over two percent of the stock's outstanding float is currently held short. The company ended the second quarter with nearly $720 million in cash and marketable securities after posting a GAAP net loss of -£0.41 a share in the quarter. The company only burned through a bit over $10 million in cash to fund all operations during the last quarter. Verdict The current analyst consensus has the company losing 90 cents a share on $69 million in revenue in FY2022. In FY2023, losses are expected to increase to nearly $1.50 a shares as revenues fall. It should be noted, that few firms have projections on Exscientia's and there is a very wide range to earnings and revenue estimates. Given that all revenues in coming year will come from either developmental milestones within existing collaboration deals or upfront payments from new collaboration agreements, one can't blame analyst firms for having a very difficult time modeling future revenue streams. June Company Presentation The company has made some good progress in showing that its AI enabled platform can more effectively identify promising early stage drug candidates. This is a key reason it has garnered an impressive list of collaboration partners.
Analyseartikel • May 29

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Opbrengsten en kosten

Hoe Exscientia geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:EXAI Opbrengsten, kosten en inkomsten (GBP Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 2417-15157105
30 Jun 2421-13043111
31 Mar 2420-12938119
31 Dec 2320-14645128
30 Sep 2324-14442135
30 Jun 2322-14841139
31 Mar 2326-14142139
31 Dec 2227-11938129
30 Sep 2225-10035112
30 Jun 2236-693488
31 Mar 2229-592963
31 Dec 2127-492644
30 Sep 2127-362129
30 Jun 2110-391419
31 Mar 2113-24813
31 Dec 2010-22611
31 Dec 199-657

Kwaliteitswinsten: EXAI is momenteel verliesgevend.

Groeiende winstmarge: EXAI is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: EXAI is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 41.2% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van EXAI over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: EXAI is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 43% ).

Rendement op eigen vermogen

Hoge ROE: EXAI heeft een negatief Return on Equity ( -58.93% ), omdat het momenteel verliesgevend is.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2024/11/22 06:54
Aandelenkoers aan het einde van de dag2024/11/19 00:00
Inkomsten2024/09/30
Jaarlijkse inkomsten2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Exscientia plc wordt gevolgd door 3 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Alec StranahanBofA Global Research
Hiroshi ShibutaniGoldman Sachs
Brendan SmithTD Cowen